兴科蓉医药年报 2024

2024ANNUAL REPORT年報 Contents 78Consolidated Statement of Profit orLoss and Other Comprehensive Income79Consolidated Statement of Financial Position81Consolidated Statement of Changes in Equity82Consolidated Statement of Cash Flows85Notes to the Consolidated Financial Statements178Definitions 2Corporate Information4Financial Highlights6Chairman’s Statement8Management Discussion and Analysis25Directors and Senior Management32Report of the Directors49Corporate Governance Report71Independent Auditor’s Report Corporate Information公司資料 2024326 BOARD OF DIRECTORSExecutive Directors Mr. Huang Xiangbin(Chairman)Mr. Huang Zhijian(Vice Chairman)(appointed with effect from 26 March 2024)Mr. Lei Shifeng 20241224 Non-executive DirectorMs. Jing Huan(appointed with effect from 24 December 2024) Independent Non-executive Directors Mr. Lau Ying KitMr. Liu WenfangMr. Wang QingMr. Bai Zhizhong AUDIT COMMITTEE Mr. Lau Ying Kit(Chairman)Mr. Liu WenfangMr. Wang QingMr. Bai Zhizhong REMUNERATION COMMITTEE Mr. Wang Qing(Chairman)Mr. Liu WenfangMr. Bai ZhizhongMr. Lei Shifeng NOMINATION COMMITTEE Mr. Huang Xiangbin(Chairman)Mr. Liu WenfangMr. Lau Ying Kit INTERNAL CONTROL AND CORPORATEGOVERNANCE COMMITTEE Mr. Lau Ying Kit(Chairman)Mr. Wang QingMr. Liu WenfangMr. Bai ZhizhongMr. Lei Shifeng 20243262024326 AUTHORISED REPRESENTATIVES Mr. Huang XiangbinMs. Peng Yunlu(appointed with effect from 26 March 2024)Mr. Li Kin Wai(resigned with effect from 26 March 2024) COMPANY SECRETARIESMs. Peng YunluMr. Li Kin Wai(resigned with effect from 26 March 2024) 2024326 PO Box 309Ugland HouseGrand Cayman, KY1-1104Cayman Islands REGISTERED OFFICE PO Box 309Ugland HouseGrand Cayman, KY1-1104Cayman Islands Corporate Information (Continued) CORPORATE HEADQUARTERS 1700E5-1805 E5-1805, Global CentreNo. 1700, North Section of Tianfu AvenueHigh-Tech Zone, ChengduSichuanPRC PRINCIPAL PLACE OF BUSINESSIN HONG KONG 1112403 Room 2403, Wing On Centre111 Connaught Road CentralHong Kong CAYMAN ISLANDS PRINCIPAL SHAREREGISTRAR AND TRANSFER OFFICE Maples Fund Services (Cayman) LimitedP.O. Box 1093, Boundary HallCricket SquareGrand Cayman, KY1-1102Cayman Islands Maples Fund Services (Cayman) LimitedP.O. Box 1093, Boundary HallCricket SquareGrand Cayman, KY1-1102Cayman Islands HONG KONG BRANCH SHARE REGISTRAR Computershare Hong Kong Investor Services LimitedShops 1712-1716, 17/F, Hopewell Centre,183 Queen’s Road EastWan ChaiHong Kong 1831717121716 HONG KONG LEGAL ADVISERTian Yuan Law Firm LLP AUDITOR CL Partners CPA LimitedCertified Public AccountantsRegistered Public Interest Entity Auditor STOCK CODE ON THE MAIN BOARD OF THESTOCK EXCHANGE OF HONG KONG LIMITED6833 6833 www.sinco-pharm.com COMPANY’S WEBSITEwww.sinco-pharm.com LISTING DATE10 March 2016 2016310 Financial Highlights •Revenue of the Group increased by 11.1% or RMB281.2 million toRMB2,821.3 million for the Reporting Period (2023: RMB2,540.1million), among which revenue from sales of human albumin solutionincreased by approximately RMB276.5 million, mainly benefited fromthe increase in sales volume. •11.1%281.22,821.320232,540.1276.5 •Gross profit of the Group decreased by RMB23.4 million to RMB299.9million for the Reporting Period (2023: RMB323.3 million), while grossprofit margin decreased from 12.7% in 2023 to 10.6% for the ReportingPeriod. The decrease in gross profit was mainly due to the increase incost of sales of human albumin was greater than the increase in its salesrevenue, which was caused by the increased purchase cost as a result ofthe further depreciation of the RMB against the US$. •23.4299.92023323.3202312.7%10.6% •42.0202342.40.4 •Net profit of the Group was amounted to RMB42.0 million for theReporting Period, which was slightly decreased by RMB0.4 million ascompared to the net profit of 2023 amounted to RMB42.4 million. •42.0202342.40.9% •During the Reporting Period, net profit attributable to owners ofthe Company amounted to RMB42.0 million (2023: net profit ofRMB42.4 million), representing a slightly decrease of 0.9%. •Basic and diluted earnings per share amounted to RMB0.02 for theReporting Period (2023: basic and diluted earnings per share ofRMB0.02). •0.0220230.02 •The Board resolved to declare a final dividend in respect of the yearended 31 December 2024 of HK0.20 cents (2023: final dividend inrespect of the year ended 31 December 2023 of HK0.39 cents) perordinary share, in an aggregate amount of HK$4,000,000 (2023:HK$8,000,000). The dividend has been proposed by the Directors ofthe Company and is subject to approval by the shareholders at theforthcoming general meeting. The final dividend has been calculatedby reference to the 2,032,890,585 issued shares outstanding as atthe date of this report. •202412310.202023202312 310.394,000,00020238,000,0002,032,890,585 Chairman’s Statement Dear Shareholders, On behalf of the Board, I would like to express my sincere gratitude to allShareholders for their concern and support to